DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Votrient is a drug marketed by Novartis and is included in one NDA. There are three patents protecting this drug.
This drug has forty patent family members in twenty-five countries.
The generic ingredient in VOTRIENT is pazopanib hydrochloride. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pazopanib hydrochloride profile page.
Votrient was eligible for patent challenges on October 19, 2013.
By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 19, 2023. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for VOTRIENT
|Finished Product Suppliers / Packagers:||1|
|Raw Ingredient (Bulk) Api Vendors:||87|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price information for VOTRIENT|
|What excipients (inactive ingredients) are in VOTRIENT?||VOTRIENT excipients list|
|DailyMed Link:||VOTRIENT at DailyMed|
DrugPatentWatch® Estimated Generic Entry Opportunity Date for VOTRIENT
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for VOTRIENT
Identify potential brand extensions & 505(b)(2) entrants
|Cure HHT||Phase 2/Phase 3|
|University of Washington||Phase 1/Phase 2|
|Academic and Community Cancer Research United||Phase 2|
|Country||Patent Number||Estimated Expiration|
|Norway||20032831||Get Started for $10|
|Japan||4253188||Get Started for $10|
|Poland||363243||Get Started for $10|
|Portugal||1343782||Get Started for $10|
|Israel||156306||Get Started for $10|
|Cyprus||1117079||Get Started for $10|
|Denmark||1343782||Get Started for $10|
|>Country||>Patent Number||>Estimated Expiration|
|Patent Number||Supplementary Protection Certificate||SPC Country||SPC Expiration||SPC Description|
|1343782||389||Finland||Get Started for $10|
|1343782||10C0037||France||Get Started for $10||PRODUCT NAME: PAZOPANIB; REGISTRATION NO/DATE: EU/1/110/628/001 20100614|
|1343782||C300456||Netherlands||Get Started for $10||PRODUCT NAME: PAZOPANIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT, IN HET BIJZONDER PAZOPANIB HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/10/628/001-004 20100614|
|1343782||2010C/030||Belgium||Get Started for $10||PRODUCT NAME: PAZOPANIB, OPTIONNELLEMENT SOUS LA FORME DE SON SEL PHARMACEUTIQUEMENT ACCEPTABLE OU DE SON SOLVATE; AUTHORISATION NUMBER AND DATE: EU/1/110/628/01 20100616|
|1343782||91710||Luxembourg||Get Started for $10||91710, EXPIRES: 20250614|
|1343782||122010000038||Germany||Get Started for $10||PRODUCT NAME: PAZOPANIB ODER EIN SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/10/628/001-004 20100614|
|1343782||C01343782/01||Switzerland||Get Started for $10||FORMER OWNER: GLAXOSMITHKLINE LLC, US|
|>Patent Number||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration||>SPC Description|